BioInvent and SkylineDx to Collaborate on Patient Stratification to Maximize Impact of Treatment with BI-1206

- Agreement to characterize gene expression and immunological signature of tumors

- SkylineDx focuses on discovery and development of novel gene-based biomarkers

LUND, Sweden, March 24, 2020 /PRNewswire/ -- BioInvent International AB ("BioInvent") (OMXS: BINV) today announces an agreement with SkylineDx to characterize the gene expression and immunological    signatures in tumors of patients pre- and post-treatment with BI-1206.

SkylineDx is a molecular diagnostics company which focuses on the discovery of novel gene-based biomarkers with high clinical utility for patient targeting and stratification. Headquartered in Rotterdam, the Netherlands, SkylineDx operates a CAP/CLIA certified laboratory in San Diego, California, USA.

Together the companies will research and develop predictive immunological signatures to help identify patients with non-Hodgkin lymphoma (NHL) and solid cancers who are likely to show clinical responses if treated with BI-1206, BioInvent's lead product candidate.

Martin Welschof, CEO of BioInvent, said: "We are delighted to be working with SkylineDx, a company that has built up a great deal of expertise in molecular diagnostics, which is essential for the development of targeted cancer therapies. Identifying the right patients who are likely to respond to treatment with BI-1206 will constitute a major asset in the development of this promising treatment and, along with FcγRIIB expression levels, should support the extension of its use to other malignancies."

Dharminder Chahal, CEO of SkylineDx, said: "It is a real pleasure to announce our collaboration with Bioinvent, a true pioneer in promising new cancer treatments. As a diagnostics company, we always strive for precision medicine. Joining forces to identify true responders in early phase pharmaceutical trials, will make mark an important milestone towards that goal."

About BioInvent

BioInvent International AB (OMXS: BINV) is a clinical stage company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of hematological cancer and solid tumors, respectively. Two preclinical programs in solid tumors are expected to have entered clinical trials by the end of 2020. The Company's validated, proprietary F.I.R.S.T™  technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.

The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.

About SkylineDx

SkylineDx is a high-tech commercial-stage biotech company headquartered in Rotterdam, the Netherlands and a CAP/CLIA certified laboratory in San Diego, California, USA. The company uses its expertise to bridge the gap between academically discovered gene expression signatures and commercially available diagnostic products with high clinical utility. With the focus on diagnostics, SkylineDx assists healthcare professionals in accurately determining the type or status of the disease or to predict a patient's response to a specific treatment. Based on the test results, healthcare professionals can tailor the treatment to the individual patient. To learn more, please visit www.skylinedx.com.

BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

This information was brought to you by Cision http://news.cision.com

The following files are available for download: